Tag: Prescription Drugs

No significant improvement seen in median time to resolution of symptoms with ivermectin versus placebo

Estimated change in mean body weight to week 68 was −9.6 percent with semaglutide 2.4 mg versus −3.4 percent with placebo

Terlipressin is more effective for reversal of HRS but is associated with more adverse events and death due to respiratory disorders

Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC

Improved outcomes, including more organ support-free days, reduced mortality, seen with tocilizumab, sarilumab

Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma

Significantly more women had reduced menstrual bleeding with once-daily relugolix combination therapy versus placebo

Avacopan noninferior to prednisone taper for remission at week 26, superior to prednisone taper for sustained remission at week 52

Overall survival longer compared with standard chemo for disease progression following platinum-based chemo and PD-1 or PD-L1 inhibitor

Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin